Organisers behind the push to put a marijuana repeal measure on Arizona’s November ballot have officially abandoned the effort, marking the second state-level recriminalisation campaign to collapse this year. The retreat reinforces a pattern industry advocates have flagged for months: repeal coalitions are struggling to convert public discomfort with retail expansion into the political infrastructure needed to actually overturn voter-approved markets. Operators in Arizona can now plan capital allocation through 2027 without the overhang of an existential ballot risk.

Source: NORML

Idaho’s medical cannabis ballot campaign has filed roughly twice the signatures needed to qualify, a striking show of force in one of the most restrictive states in the country. If certified and approved, Idaho would join the long tail of holdout jurisdictions converting under the post-rescheduling tailwind, opening another small but politically significant market for vertically integrated operators. The signature surplus also gives the campaign a meaningful buffer against the legal challenges that typically follow rural-state initiatives.

Source: Cannabis Business Times

A new study from Cornell finds that adult-use legalisation has produced sharp drops in cannabis arrests across legal-market states, but that Black residents remain disproportionately represented in the prosecutions that do occur. The findings cut both ways for advocates: they validate the headline equity argument for legalisation while underscoring that decriminalisation alone has not closed enforcement gaps, and they hand policymakers a fresh empirical case for expungement and policing-reform riders in upcoming reform bills.

Source: Cornell Chronicle

A new lawsuit accuses several of the largest US cannabis operators of improperly marketing recreational products as medicine, escalating a legal-risk theme that had been simmering in the background of the rescheduling debate. The complaint sharpens the tension between the industry’s commercial interest in therapeutic positioning and the FDA-style evidence threshold federal regulators are likely to apply once Schedule III is fully implemented. Expect general counsels across the multi-state operator field to revisit packaging, in-store signage, and influencer programmes this quarter.

Source: The Free Press

Tilray has detailed a strategy that leans heavily on medical-channel growth in international markets, particularly Germany and the broader EU, while positioning its US footprint to flip more aggressively if and when interstate commerce becomes viable. The plan reads as a deliberate hedge against North American recreational margin compression, and aligns with a wider operator trend of treating regulated medical access — not adult-use — as the most defensible long-term revenue base. For investors, it is also a useful template for reading the next round of MSO and Canadian-LP earnings calls.

Source: MJBizDaily